Udayakumar Durga, Mahato Bisundev, Gabree Michele, Tsao Hensin
Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Semin Cutan Med Surg. 2010 Sep;29(3):190-5. doi: 10.1016/j.sder.2010.06.002.
In the last 2 decades, advances in genomic technologies and molecular biology have accelerated the identification of multiple genetic loci that confer risk for cutaneous melanoma. The risk alleles range from rarely occurring, high-risk variants with a strong familial predisposition to low-risk to moderate-risk variants with modest melanoma association. Although the high-risk alleles are limited to the CDKN2A and CDK4 loci, the authors of recent genome-wide association studies have uncovered a set of variants in pigmentation loci that contribute to low risk. A biological validation of these new findings would provide greater understanding of the disease. In this review we describe some of the important risk loci and their association to risk of developing cutaneous melanoma and also address the current clinical challenges in CDKN2A genetic testing.
在过去20年中,基因组技术和分子生物学的进展加速了多个导致皮肤黑色素瘤风险的基因位点的识别。风险等位基因范围从罕见的、具有强烈家族易感性的高风险变异,到与黑色素瘤关联较弱的低风险至中等风险变异。虽然高风险等位基因仅限于CDKN2A和CDK4基因座,但近期全基因组关联研究的作者们在色素沉着基因座中发现了一组导致低风险的变异。对这些新发现进行生物学验证将有助于更深入地了解该疾病。在本综述中,我们描述了一些重要的风险基因座及其与皮肤黑色素瘤发生风险的关联,同时也探讨了CDKN2A基因检测当前面临的临床挑战。